当前位置: 首页 > 详情页

A prospective study of impaired fasting glucose and type 2 diabetes in China The Kailuan study

文献详情

资源类型:

收录情况: ◇ SCIE

机构: [1]Brigham & Womens Hosp, Dept Endocrinol Diabet & Hypertens, 75 Francis St, Boston, MA 02115 USA; [2]Harvard Med Sch, Boston, MA USA; [3]Kailuan Hosp, Dept Internal Med, Tangshan, Hebei, Peoples R China; [4]Hebei Union Univ Hosp, Dept Internal Med, Tangshan, Hebei, Peoples R China; [5]Capital Med Univ, Beijing Tian Tan Hosp, Dept Neurol, Beijing, Peoples R China; [6]Brigham & Womens Hosp, Dept Rheumatol, 75 Francis St, Boston, MA 02115 USA; [7]Peoples Hosp Xinjiang Uygur Autonomous Reg, Dept Resp Med, Urumqi, Xinjiang, Peoples R China; [8]Harvard Sch Publ Hlth, Dept Nutr, Boston, MA USA; [9]Penn State Univ, Dept Nutr Sci, State Coll, PA USA; [10]Penn State Univ, Dept Nutr Sci, University Pk, PA 16802 USA; [11]Kailuan Hosp, Dept Cardiol, 57 Xinhua Rd East, Tangshan 063000, Peoples R China
出处:
ISSN:

关键词: China cohort study diabetes fasting glucose impaired fasting glucose incidence obesity

摘要:
The worldwide prevalence and incidence of diabetes and obesity are increasing in pandemic proportions. This is particularly relevant for China, where an extremely large population is growing, aging, and urbanizing. We thus conducted a prospective study to examine the prevalence and incidence of impaired fasting glucose (IFG) and diabetes, the rate at which fasting blood glucose rises, and the major modifiable risk factors associated with these outcomes in a large Chinese population from the Kailuan prospective study. A prospective cohort included 100,279 Chinese participants, aged 18 years or more, who had available information on fasting blood glucose concentrations at the start of the study (2006). Examination surveys were conducted every 2 years in 2008 and 2010. For the analyses of incident diabetes, we included 76,869 participants who were free of diabetes, cardiovascular disease, and cancer at the baseline and participants in the 2008 and/or 2010 follow-up. Diabetes was defined by a fasting blood glucose concentration >= 7mmol/L, self-reported history, or active treatment with insulin or any oral hypoglycemic agent. IFG was defined by a fasting blood glucose concentration between 5.6 and 6.9mmol/L. During the 4-year study, the prevalence of diabetes and IFG rose from 6.6% to 7.7%, and 17.3% to 22.6%, respectively. There were 17,811 incident cases of IFG and 4867 incident cases of diabetes. The age-standardized incident rate of IFG and diabetes were 62.6/1000 person-years (51.2/1000 person-years in women and 73.8/1000 person-years in men) and 10.0/1000 person-years (7.8/ 1000 person-years in women and 12.1/1000 person-years in men), respectively. We observed steady increases in fasting blood glucose with body anthropometrics and in every defined category of body mass index, including in those traditionally considered to be well within the "normal" range. In this large longitudinal study of Chinese adults, we observed a high prevalence and incidence of IFG and diabetes over 4 years of follow-up. Our findings are alarming for Chinese public health since steady rises in fasting blood glucose were seen across all permutations of body habitus, even apparently very lean individuals.

基金:
语种:
被引次数:
WOS:
PubmedID:
中科院(CAS)分区:
出版当年[2015]版:
大类 | 2 区 医学
小类 | 2 区 医学:内科
最新[2023]版:
大类 | 4 区 医学
小类 | 4 区 医学:内科
JCR分区:
出版当年[2014]版:
Q1 MEDICINE, GENERAL & INTERNAL
最新[2023]版:
Q2 MEDICINE, GENERAL & INTERNAL

影响因子: 最新[2023版] 最新五年平均 出版当年[2014版] 出版当年五年平均 出版前一年[2013版] 出版后一年[2015版]

第一作者:
第一作者机构: [1]Brigham & Womens Hosp, Dept Endocrinol Diabet & Hypertens, 75 Francis St, Boston, MA 02115 USA; [2]Harvard Med Sch, Boston, MA USA;
通讯作者:
通讯机构: [3]Kailuan Hosp, Dept Internal Med, Tangshan, Hebei, Peoples R China; [9]Penn State Univ, Dept Nutr Sci, State Coll, PA USA; [10]Penn State Univ, Dept Nutr Sci, University Pk, PA 16802 USA; [11]Kailuan Hosp, Dept Cardiol, 57 Xinhua Rd East, Tangshan 063000, Peoples R China
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:16461 今日访问量:0 总访问量:871 更新日期:2025-01-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 首都医科大学宣武医院 技术支持:重庆聚合科技有限公司 地址:北京市西城区长椿街45号宣武医院